The Molecular Detection and Clinical Significance of ALK Rearrangement in Selected Advanced Non-Small Cell Lung Cancer: ALK Expression Provides Insights into ALK Targeted Therapy
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Molecular Detection and Clinical Significance of ALK Rearrangement in Selected Advanced Non-Small Cell Lung Cancer: ALK Expression Provides Insights into ALK Targeted Therapy
Authors
Keywords
Non-small cell lung cancer, Immunohistochemistry techniques, Fluorescent in situ hybridization, Adenocarcinomas, Cancer treatment, Radiation therapy, Oncology, Clinical trials
Journal
PLoS One
Volume 9, Issue 1, Pages e84501
Publisher
Public Library of Science (PLoS)
Online
2014-01-04
DOI
10.1371/journal.pone.0084501
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4–ALK-rearranged non–small–cell lung cancer harbored coexisting EGFRmutation
- (2013) Akihiko Miyanaga et al. BMC CANCER
- Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis
- (2013) Chee Khoon Lee et al. JNCI-Journal of the National Cancer Institute
- Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
- (2013) Neal I. Lindeman et al. Journal of Thoracic Oncology
- Recommendations for the Analysis of ALK Gene Rearrangements in Non–Small-Cell Lung Cancer: A Consensus of the Italian Association of Medical Oncology and the Italian Society of Pathology and Cytopathology
- (2013) Antonio Marchetti et al. Journal of Thoracic Oncology
- CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study
- (2013) Takashi Seto et al. LANCET ONCOLOGY
- Comparison of Reverse Transcription-Polymerase Chain Reaction, Immunohistochemistry, and Fluorescence In Situ Hybridization Methodologies for Detection of Echinoderm Microtubule-Associated Proteinlike 4–Anaplastic Lymphoma Kinase Fusion–Positive Non–Small Cell Lung Carcinoma: Implications for Optimal Clinical Testing
- (2012) Michelle L. Wallander et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Association ofEGFRmutation orALKrearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinoma
- (2012) Shengxiang Ren et al. CANCER
- Crizotinib for ALK-Rearranged Non-Small Cell Lung Cancer: A New Targeted Therapy for a New Target
- (2012) L. Gandhi et al. CLINICAL CANCER RESEARCH
- A Dramatic Response to Crizotinib in a Non–Small-Cell Lung Cancer Patient with IHC-Positive and FISH-Negative ALK
- (2012) Jong-Mu Sun et al. Journal of Thoracic Oncology
- Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients
- (2012) Heae Surng Park et al. LUNG CANCER
- Crizotinib for the Treatment of ALK -Rearranged Non-Small Cell Lung Cancer: A Success Story to Usher in the Second Decade of Molecular Targeted Therapy in Oncology
- (2012) Sai-Hong Ignatius Ou et al. ONCOLOGIST
- EML4-ALK Rearrangement and Its Clinical Significance in Chinese Patients with Advanced Non-Small Cell Lung Cancer
- (2012) Zhijie Wang et al. ONCOLOGY
- EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations
- (2012) Erik Thunnissen et al. VIRCHOWS ARCHIV
- Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer
- (2011) June Koo Lee et al. CANCER
- Lung Adenocarcinoma with Concurrent Exon 19 EGFR Mutation and ALK Rearrangement Responding to Erlotinib
- (2011) Sanjay Popat et al. Journal of Thoracic Oncology
- Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed
- (2011) D. Ross Camidge et al. Journal of Thoracic Oncology
- Correlation of IHC and FISH for ALK Gene Rearrangement in Non-small Cell Lung Carcinoma: IHC Score Algorithm for FISH
- (2011) Eunhee S. Yi et al. Journal of Thoracic Oncology
- Anaplastic Lymphoma Kinase Translocation: A Predictive Biomarker of Pemetrexed in Patients with Non-small Cell Lung Cancer
- (2011) Jeong-Ok Lee et al. Journal of Thoracic Oncology
- Detection of ALK Gene Rearrangement in Non-small Cell Lung Cancer: A Comparison of Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization with Correlation of ALK Protein Expression
- (2011) Hyojin Kim et al. Journal of Thoracic Oncology
- International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
- (2011) William D. Travis et al. Journal of Thoracic Oncology
- Worse Disease-Free Survival in Never-Smokers with ALK+ Lung Adenocarcinoma
- (2011) Ping Yang et al. Journal of Thoracic Oncology
- EML4-ALK Translocation Predicts Better Outcome in Lung Adenocarcinoma Patients with Wild-Type EGFR
- (2011) Shang-Gin Wu et al. Journal of Thoracic Oncology
- Dual IHC and FISH Testing for ALK Gene Rearrangement in Lung Adenocarcinomas in a Routine Practice: A French Study
- (2011) Anne McLeer-Florin et al. Journal of Thoracic Oncology
- Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
- (2011) Alice T Shaw et al. LANCET ONCOLOGY
- More on Crizotinib
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment
- (2010) D. R. Camidge et al. CLINICAL CANCER RESEARCH
- Good Response to Gefitinib in Lung Adenocarcinoma Harboring Coexisting EML4-ALK Fusion Gene and EGFR Mutation
- (2010) Yao-Wen Kuo et al. Journal of Thoracic Oncology
- EGFR and EML4-ALK gene mutations in NSCLC: A case report of erlotinib-resistant patient with both concomitant mutations
- (2010) M. Tiseo et al. LUNG CANCER
- Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression
- (2010) Xuchao Zhang et al. Molecular Cancer
- EML4-ALK Rearrangement in Non-Small Cell Lung Cancer and Non-Tumor Lung Tissues
- (2009) Maria Paola Martelli et al. AMERICAN JOURNAL OF PATHOLOGY
- Clinicopathologic Features of Non-Small-Cell Lung Cancer with EML4–ALK Fusion Gene
- (2009) Tsuyoshi Takahashi et al. ANNALS OF SURGICAL ONCOLOGY
- TheEML4-ALKfusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-typeEGFRandKRAS
- (2009) Daisy Wing-Sze Wong et al. CANCER
- Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population
- (2009) S. J. Rodig et al. CLINICAL CANCER RESEARCH
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
- (2009) Alice T. Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
- EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer
- (2008) J. P. Koivunen et al. CLINICAL CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now